An open-label, parallel-group, multiple-dose, steady-state pharmacokinetic study of SUBOXONE@16 mg/4 mg and 24 mg/6 mg in opioid-dependent patients undergoing withdrawal treatment
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Buprenorphine/naloxone (Primary)
- Indications Opioid-related disorders
- Focus Adverse reactions; Pharmacokinetics
Most Recent Events
- 21 Jun 2019 New trial record
- 13 Jun 2019 Results published in the Drugs in R and D